Novartis buys Ebner's Roche stake as CFO (Chief Financial Officer) departs
This article was originally published in Clinica
Novartis has bought holdings in pharmaceuticals and diagnostics group Roche which were owned by BZ Group Holdings, a Swiss financial group owned by Martin Ebner. The rival Swiss drugs company paid SFr4.83 billion ($2.77 billion) The acquisition of 20% of bearer shares available does not change the majority holding of voting shares owned by family interests descending from the founder of the group Fritz Hoffmann-La Roche.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.